Online Exclusive Article

Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events

Kathleen Clifford

Amanda Copeland

Gregory Knutzen

Ellen Samuelson

Laurie Grove

Karen Schiavo

brentuximab vedotin, adverse events, peripheral neuropathy, management
CJON 2018, 22(4), E103-E114. DOI: 10.1188/18.CJON.E103-E114

Background: Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30-expressing cells.

Objectives: This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic anaplastic large cell lymphoma trials, and shares practical tips that may help decrease occurrence and severity.

Methods: Peer-reviewed literature was surveyed to collect safety data from sponsored clinical trials of BV and to compile associated management guidelines.

Findings: Peripheral neuropathy was the most common BV-associated AE across clinical trials. Other clinically relevant AEs included neutropenia, infection, and infusion-related reactions. Awareness of and preparedness for these common BV-associated AEs and other less common but significant AEs will help nurse clinicians and patients maximize the clinical benefit for patients receiving BV.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.